Anticancer research
-
Anticancer research · Oct 2010
Multicenter StudyUse of paclitaxel for advanced ovarian cancer in clinical practice: analysis of 541 patients. Results from a German multi-centre observational study.
Paclitaxel is one of the most common antitumour agents paclitaxel for the treatment of primary and relapsed ovarian cancer. Based on a German multicentre observational study, this article reflects the use of paclitaxel in German daily clinical practice. ⋯ Paclitaxel is broadly used in the management of patients with primary and relapsed ovarian cancer. The toxicity profile observed seems to be within the range of the results of clinical phase-III studies. The doses applied and the schedules based on the official recommendation of the working groups seem to have been influenced by international studies.
-
Anticancer research · Oct 2010
Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients.
Venous thromboembolism (VTE) is associated with cancer. Cancer patient with thromboembolism have poorer prognosis. This study assessed the risk and mortality in pancreatic cancer patients who develop VTE. ⋯ Patients with body of the pancreas and stage IV tumors had increased risk of developing VTE. There was no survival difference between patients with VTE compared to those without.